These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7860418)

  • 21. Age-related decrease in hypothalamic gonadotropin-releasing hormone (GnRH) gene expression, but not pituitary responsiveness to GnRH, in the male Brown Norway rat.
    Gruenewald DA; Naai MA; Marck BT; Matsumoto AM
    J Androl; 2000; 21(1):72-84. PubMed ID: 10670522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoprolactinemia does not prevent restoration of normal spermatogenesis in gonadotropin-suppressed, testosterone-replaced rats.
    Awoniji CA; Roberts D; Chandrashekar V; Hurst BS; Tucker KE; Schlaff WD
    J Androl; 1996; 17(1):35-40. PubMed ID: 8833739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum FSH and LH levels in men after administration of a long-acting LH-RH preparation.
    Laczi F; Julesz J; Bártfai G; Sas M; László FA
    Acta Med Acad Sci Hung; 1982; 39(3-4):125-31. PubMed ID: 6821016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follicle-stimulating hormone is required for the initial phase of spermatogenic restoration in adult rats following gonadotropin suppression.
    Meachem SJ; Wreford NG; Stanton PG; Robertson DM; McLachlan RI
    J Androl; 1998; 19(6):725-35. PubMed ID: 9876024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal effects of GnRH agonist in the human male: II. Testosterone enhances gonadotrophin suppression induced by GnRH agonist.
    Bhasin S; Heber D; Steiner B; Peterson M; Blaisch B; Campfield LA; Swerdloff RS
    Clin Endocrinol (Oxf); 1984 Feb; 20(2):119-28. PubMed ID: 6232019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of spermatogenesis in dibromochloropropane (DBCP)-treated rats by hormone suppression.
    Meistrich ML; Wilson G; Porter KL; Huhtaniemi I; Shetty G; Shuttlesworth GA
    Toxicol Sci; 2003 Dec; 76(2):418-26. PubMed ID: 14514963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
    Wong SL; Lau DT; Baughman SA; Fotheringham N; Menchaca D; Garnick MB
    J Clin Pharmacol; 2004 May; 44(5):495-502. PubMed ID: 15102870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of delayed puberty by intranasal application of gonadotropin-releasing hormone (GnRH).
    Happ J; Schmitz V; Cordes U; Krause U; Atzpodien W; Beyer J
    Int J Fertil; 1980; 25(3):247-55. PubMed ID: 6108936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressive action of norethisterone enanthate and acetate on gonadotropin. (FSH and LH) levels. Radioimmunoassay in eugonadal and postmenopausal women.
    Franchimont P; Cession G; Ayalon D; Mutsers A; Legros JJ
    Obstet Gynecol; 1970 Jul; 36(1):93-100. PubMed ID: 5422095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal effects of GnRH agonist in the human male: an approach to male contraception using combined androgen and GnRH agonist treatment.
    Swerdloff RS; Handelsman DJ; Bhasin S
    J Steroid Biochem; 1985 Nov; 23(5B):855-61. PubMed ID: 2934582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of testosterone on cognition in young adult male rhesus monkeys.
    Lacreuse A; Chiavetta MR; Shirai AA; Meyer JS; Grow DR
    Physiol Behav; 2009 Dec; 98(5):524-31. PubMed ID: 19712691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum bioactive and immunoreactive follicle stimulating hormone during chronic treatment with gonadotropin releasing hormone agonist in elderly men.
    Matzkin H; Braf Z; Dekel N
    Horm Metab Res; 1991 Feb; 23(2):76-80. PubMed ID: 1710593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of gonadotropin-releasing hormone on bioactivity of follicle-stimulating hormone (FSH) and microstructure of FSH, luteinizing hormone and sex hormone-binding globulin in a testosterone-based contraceptive trial: evaluation of responders and non-responders.
    Simoni M; Peters J; Behre HM; Kliesch S; Leifke E; Nieschlag E
    Eur J Endocrinol; 1996 Oct; 135(4):433-9. PubMed ID: 8921825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy.
    Huhtaniemi IT; Dahl KD; Rannikko S; Hsueh AJ
    J Clin Endocrinol Metab; 1988 Feb; 66(2):308-13. PubMed ID: 3123510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
    Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
    J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.
    Beer TM; Ryan C; Bhat G; Garnick M;
    Anticancer Drugs; 2006 Oct; 17(9):1075-9. PubMed ID: 17001181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term GnRH-agonist administration revealed a GnRH-independent mechanism stimulating FSH discharge in humans.
    Genazzani AD; Massolo F; Ferrari E; Gandolfi A; Petraglia F; Genazzani AR
    Eur J Endocrinol; 1996 Jan; 134(1):77-83. PubMed ID: 8590961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.
    Bhasin S; Swerdloff RS; Steiner B; Peterson MA; Meridores T; Galmirini M; Pandian MR; Goldberg R; Berman N
    J Clin Endocrinol Metab; 1992 Jan; 74(1):75-83. PubMed ID: 1727832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.